Nouveau Life Pharmaceuticals, Inc. Stocks

$ 0Last Updated 20.03.2026

Issuer Rating

Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 90000

Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable price performance

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Nouveau Life Pharmaceuticals, Inc., a development stage company, engages in the development of nutraceuticals products. It provides natural alternatives and prescription drugs. The company was formerly known as Hybrid Fuels, Inc. and changed its name to Nouveau Life Pharmaceuticals, Inc. in May 2012. Nouveau Life Pharmaceuticals, Inc. was incorporated in 1998 and is based in Ft. Lauderdale, Florida. Nouveau Life Pharmaceuticals, Inc. operates as a subsidiary of EMG Marketing Solutions, Inc.

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks